W.H. Wilson Tang, MD; Gary S. Francis, MD


J Am Coll Cardiol. 2010;55(7):688-696. 

In This Article


It is refreshing to witness a year of exciting advancements in HF. Although the core drug and device therapeutic approaches remain largely unchanged, knowledge gained from this year's wide range of publications will likely shape the focus of research to come. We may see much more focus on the expanding population of patients with advanced HF who may benefit from devices (both CRT and VAD). It could be in the form of refining patient selection criteria (using biomarkers or other phenotypes) and exploring strategies for post-procedure optimization. Appropriateness of testing and therapeutic interventions will likely be scrutinized with increasing health care costs and regulations, and performance measures will likely be established regardless of whether there is any direct supporting evidence for their effectiveness. That being said, many leads for novel diagnostic and therapeutic approaches are maturing, and we hope in the near future to see advances in early prevention in the pathogenesis and decompensation of HF.